DPYSL2 and neuropathic pain: These alterations of CRMP2 phosphorylation status both result in increased CRMP2 SUMOylation (Dustrude et al., 2016) and provide a molecular basis for the increased CRMP2 SUMOylation observed in neuropathic pain (Moutal et al., 2017).